OKYO Pharma Limited Director/PDMR Shareholding (3024K)
01 September 2021 - 4:00PM
UK Regulatory
TIDMOKYO
RNS Number : 3024K
OKYO Pharma Limited
01 September 2021
OKYO Pharma Limited
("OKYO" or the "Company")
Grant of options - Director dealings
London, 1 September, 2021 - OKYO Pharma Limited (LSE: OKYO)
("OKYO" or the "Company"), the life sciences and biotechnology
company, focused on the discovery and development of novel
molecules to treat inflammatory dry eye diseases and chronic pain,
is pleased to announce , announces that the board of directors of
the Company (the "Board" or "Directors"), with Mr Brancaccio
absenting himself on grounds of interest, has awarded the following
options on 31 August 2021.
(a) Gary Jacob
Mr Jacob has been awarded options to acquire 13,000,000 ordinary
shares in the capital of the Company. The options are exercisable
at a price of 4.9 pence per share (being the mid-market closing
price of the Company's shares traded on the LSE on 31 August 2021).
The options will vest in equal tranches over four years beginning
on the date of grant.
Keeren Shah
Ms Shah has been awarded options to acquire 500,000 ordinary
shares in the capital of the Company. The options are exercisable
at a price of 4.9 pence per share (being the mid-market closing
price of the Company's shares traded on the LSE on 31 August 2021).
The options will vest in equal tranches over four years beginning
on the date of grant.
(b) John Brancaccio
Mr Brancaccio has been awarded options to acquire 900,000
ordinary shares in the capital of the Company. The options are
exercisable at a price of 4.9 pence per share (being the mid-market
closing price of the Company's shares traded on the LSE on 31
August 2021). The options will vest in equal tranches over four
years beginning on the date of grant.
This information set out below is provided in accordance with
Article 19(3) of EU Regulation 596/2014.
1. Details of PDMR / person closely associated
a) Name (i) Gary Jacob
(ii) Keeren Shah
(iii) John Brancaccio
------------------ --------------------------------------------
2. Reason for the notification
----------------------------------------------------------------
a) Position (i) Chief Executive Officer
/ status (ii) Chief Financial Officer
(iIi) Non-Executive Director
------------------ --------------------------------------------
b) Initial Initial notification
notification
/amendment
------------------ --------------------------------------------
3. Details of the issuer
----------------------------------------------------------------
a) Name OKYO Pharma Limited
------------------ --------------------------------------------
b) LEI 213800VVN5CB56Y15A05
------------------ --------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------
a) Description Ordinary Shares of no par value
of the
financial
instrument
------------------ --------------------------------------------
b) Identification ISIN for OKYO Pharma Limited: GG00BD3FV870
code of
the Financial
Instrument
------------------ --------------------------------------------
c) Nature Grant of options
of the
transaction
------------------ --------------------------------------------
d) Price(s) Price Volume
and volume(s) (i) 4.9p (i) 13,000,000
(ii) 4.9p (ii) 500,000
(iii) 4.9p (iii) 900,000
------------------ --------------------------------------------
f) Date of 31 August 2021
the transaction
------------------ --------------------------------------------
g) Place of XLON
the transaction
------------------ --------------------------------------------
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
Optiva Securities Limited Robert Emmet + 44 (0)20 3981 4173
For further information, please visit the Company's website at
www.okyopharma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHKFLFXFVLLBBX
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024